Table 2 Changes in detrended fluctuation analysis (DFA) values, Parkinson’s disease sleep scale (PDSS) and unified Parkinson’s disease rating scale (UPDRS)
From: Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson’s disease
Variable | Mean changes from baseline (95%CI) | Between group difference (96%CI) | ||
|---|---|---|---|---|
YXQN | Placebo | YXQN vs Placebo | P value | |
α value of DA | ||||
Week 8 | −0.9 [−1.1 to −0.7] | −0.2 [−0.3 to 0.1] | −0.7 [−1.0 to −0.8] | 0.056 |
Week 12 | −1.0 [−1.2 to −0.7] | −0.1 [−0.3 to 0.2] | −0.8 [−1.1 to −0.7] | 0.051 |
Week 16 | −0.9 [−1.1 to −0.6] | −0.2 [−0.2 to 0.3] | −0.9 [−1.1 to −0.7] | 0.072 |
α value of EA | ||||
Week 8 | −1.1 [−1.4 to −0.6] | −0.1 [−0.1 to 0.2] | −1.0 [−1.3 to −0.5] | 0.048 |
Week 12 | −0.9 [−1.0 to −0.6]* | 0.1 [−0.3 to 0.4] | −1.1 [−1.6 to −0.7] | 0.036 |
Week 16 | −0.9 [−1.1 to −0.7]* | −0.2 [−0.4 to 0.3] | −0.9 [−1.3 to −0.8] | 0.041 |
α value of NA | ||||
Week 8 | 1.0 [0.8 to 1.6]* | −0.3 [−0.6 to 0.4] | 1.1 [0.7 to 1.5] | 0.017 |
Week 12 | 1.1 [0.7 to 1.5]* | −0.1 [−0.5 to 0.5] | 1.0 [0.6 to 1.4] | 0.038 |
Week 16 | 0.9 [0.6 to 1.7]* | −0.2 [−0.5 to 0.4] | 0.9 [0.7 to 1.6] | 0.042 |
PDSS score | ||||
Week 8 | 12.1 [7.6 to 13.7]* | 2.9 [−4.1 to 9.7] | 10.7 [6.9 to 16.5] | 0.026 |
Week 12 | 11.9 [7.1 to 14.2]* | 3.3 [−6.6 to 7.3] | 9.8 [8.7 to 15.9] | 0.029 |
Week 16 | 9.8 [7.0 to 14.6]* | 3.2 [−4.9 to 5.1] | 9.9 [7.4 to 17.6] | 0.048 |
UPDRS score | ||||
Week 8 | −6.6 [−11.4 to −2.8] | −1.7 [−2.8 to 3.9] | −4.9 [−6.7 to −2.7] | 0.076 |
Week 12 | −5.7 [−10.8 to −1.9] | −0.9 [−1.7 to 2.1] | −5.1 [−8.3 to −2.4] | 0.069 |
Week 16 | −5.2 [−8.9 to −2.1] | 2.1 [−4.2 to 6.1] | −4.6 [−7.5 to −3.1] | 0.153 |